250 related articles for article (PubMed ID: 18190862)
1. Development and application of Hsp90 inhibitors.
Solit DB; Chiosis G
Drug Discov Today; 2008 Jan; 13(1-2):38-43. PubMed ID: 18190862
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.
Chiosis G; Caldas Lopes E; Solit D
Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024
[TBL] [Abstract][Full Text] [Related]
3. Hsp90: the vulnerable chaperone.
Chiosis G; Vilenchik M; Kim J; Solit D
Drug Discov Today; 2004 Oct; 9(20):881-8. PubMed ID: 15475321
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90: a unique chemotherapeutic target.
Cullinan SB; Whitesell L
Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
[TBL] [Abstract][Full Text] [Related]
5. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
6. Hsp90 as a therapeutic target in patients with oesophageal carcinoma.
Ekman S; Bergqvist M; Tell R; Bergström S; Lennartsson J
Expert Opin Ther Targets; 2010 Mar; 14(3):317-28. PubMed ID: 20148718
[TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibitors: current development and potential in cancer therapy.
Sidera K; Patsavoudi E
Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
[TBL] [Abstract][Full Text] [Related]
8. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
Moser C; Lang SA; Stoeltzing O
Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
[TBL] [Abstract][Full Text] [Related]
9. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Workman P; Burrows F; Neckers L; Rosen N
Ann N Y Acad Sci; 2007 Oct; 1113():202-16. PubMed ID: 17513464
[TBL] [Abstract][Full Text] [Related]
10. HSP90 inhibitors for cancer therapy and overcoming drug resistance.
Jhaveri K; Modi S
Adv Pharmacol; 2012; 65():471-517. PubMed ID: 22959035
[TBL] [Abstract][Full Text] [Related]
11. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
12. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive.
Chiosis G; Neckers L
ACS Chem Biol; 2006 Jun; 1(5):279-84. PubMed ID: 17163756
[TBL] [Abstract][Full Text] [Related]
13. The third age of antimicrobial therapy.
Casadevall A
Clin Infect Dis; 2006 May; 42(10):1414-6. PubMed ID: 16619153
[No Abstract] [Full Text] [Related]
14. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F; Kihara K; Neckers L
Anticancer Res; 2009 Mar; 29(3):797-807. PubMed ID: 19414312
[TBL] [Abstract][Full Text] [Related]
15. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
17. The fungal Achilles' heel: targeting Hsp90 to cripple fungal pathogens.
Cowen LE
Curr Opin Microbiol; 2013 Aug; 16(4):377-84. PubMed ID: 23588026
[TBL] [Abstract][Full Text] [Related]
18. Fragment-based identification of Hsp90 inhibitors.
Barker JJ; Barker O; Boggio R; Chauhan V; Cheng RK; Corden V; Courtney SM; Edwards N; Falque VM; Fusar F; Gardiner M; Hamelin EM; Hesterkamp T; Ichihara O; Jones RS; Mather O; Mercurio C; Minucci S; Montalbetti CA; Müller A; Patel D; Phillips BG; Varasi M; Whittaker M; Winkler D; Yarnold CJ
ChemMedChem; 2009 Jun; 4(6):963-6. PubMed ID: 19301319
[TBL] [Abstract][Full Text] [Related]
19. HSP90: a promising broad-spectrum antiviral drug target.
Wang Y; Jin F; Wang R; Li F; Wu Y; Kitazato K; Wang Y
Arch Virol; 2017 Nov; 162(11):3269-3282. PubMed ID: 28780632
[TBL] [Abstract][Full Text] [Related]
20. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies.
Huth JR; Park C; Petros AM; Kunzer AR; Wendt MD; Wang X; Lynch CL; Mack JC; Swift KM; Judge RA; Chen J; Richardson PL; Jin S; Tahir SK; Matayoshi ED; Dorwin SA; Ladror US; Severin JM; Walter KA; Bartley DM; Fesik SW; Elmore SW; Hajduk PJ
Chem Biol Drug Des; 2007 Jul; 70(1):1-12. PubMed ID: 17630989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
